Please wait while the formulary information is being retrieved.
INTRAROSA (PRASTERONE (DHEA))
- Dyspareunia due to menopausal vulvovaginal atrophy
6.5 mg vaginal insert
- Insert 1 vaginal insert (6.5 mg) by vaginal route once daily at bedtime
Dyspareunia due to menopausal vulvovaginal atrophy
- Insert 1 vaginal insert (6.5 mg) by vaginal route once daily at bedtime
- None
Contraindicated
- None
Severe
Moderate
- None
- Lactating mother
- Pregnancy
- Prostatic carcinoma
Contraindicated
- Altered mental status
- Diabetes mellitus
- Disease of liver
Severe
Moderate
- None
INTRAROSA (PRASTERONE (DHEA))
- Dyspareunia due to menopausal vulvovaginal atrophy
- None
- Vaginal discharge
More Frequent
Severe
Less Severe
- Nonspecific abnormal papanicolaou smear of cervix
- None
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- None
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
None
Prasterone (dhea)
- Severity Level:
1
- Additional Notes: May have androgenic effects
Contraindicated
Prasterone (dhea)
May have androgenic effects on infant
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | May have androgenic effects on infant |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Dyspareunia due to menopausal vulvovaginal atrophy | |
| N95.2 | Postmenopausal atrophic vaginitis |
| 0-9 | A-Z |
|---|---|
| N95.2 | Postmenopausal atrophic vaginitis |
Formulary Reference Tool